Interview Transcript

This is a snippet of the transcript, sign up to read more.

We are generalist investors and don't have a specialty in the life sciences. We've been learning about life sciences companies who were high fliers, but backed off in the stock market. We are specifically focusing on companies where there's a degree to which they could place an instrument then get aftermarket recurring revenue. It is easier for us to understand the core razor blade business model. One of the companies we've been working on is 10x Genomics. We've done our dive on the company we feel more comfortable about their position in single cell than spatial, though we need to believe in the spatial opportunity to invest. Those are the companies we look for and what brought us to this conversation today.

10x announced yesterday they have a road-map for 5,000, but didn't provide any data or timeline, whereas NanoString have a tested product with data. Other companies don't have single cell like 10x, so they have nothing to lose. All they need to do is capture the market 10x created by developing the spatial market. 10x enjoyed a lifetime of monopoly in single cell, growing exponentially from 10 million to more than half a billion. Their biggest problem will be their customers switching from single cell to spatial, and they don't care whether they use 10x or Illumina. If research demands you need spatial information to study cancer and treat patients better, they will simply switch. 10x are still promoting single cell using Chromium which gives the whole transcriptome, but it lacks spatial context.

This is a snippet of the transcript, sign up to read more.

We are generalist investors and don't have a specialty in the life sciences. We've been learning about life sciences companies who were high fliers, but backed off in the stock market. We are specifically focusing on companies where there's a degree to which they could place an instrument then get aftermarket recurring revenue. It is easier for us to understand the core razor blade business model. One of the companies we've been working on is 10x Genomics. We've done our dive on the company we feel more comfortable about their position in single cell than spatial, though we need to believe in the spatial opportunity to invest. Those are the companies we look for and what brought us to this conversation today.

Visium gives multicellular spatial on a glass FFP slide, and if you pick the genes you are interested in, that gives you the biological insight. Xenium is a custom design which can validate up to 380 genes. If a company offers 6,000 genes in tissue in a single experiment, you mount the slide on Monday and get 6,000 genes of data per every single cell by Friday for a million cells, for a few thousand dollars, why would anyone do single cells, validate in multicellular on tissue with the Visium, then go to the Xenium to validate a subset of genes?

This is a snippet of the transcript, sign up to read more.

Sign up to test our content quality with a free sample of 50+ interviews